TICKERNERD
Menu
CRVOCRVOHealthcare · Biotechnology

CRVO Stock Forecast: CervoMed, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$2.62
+2.34% on the day

The 6 Wall Street analysts covering CervoMed, Inc. hold a median 12-month price target of $15 — +472.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 29 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$39.6M
Ticker Nerd rank
29 / 100
Median analyst target
$15
Analysts covering
6
Total return, dividends reinvested
1W
−4.0%
1M
−9.3%
YTD
−66.8%
1Y
−71.6%
From 52W high
−75.5%
From 52W low
+16.4%
$2
$11
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CRVO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores CervoMed, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
29 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
84
Revisions
69
Accruals
62
Growth
37
Volatility
36
Momentum
31
Issuance
28
Value
18
Quality
9

Size (84): Smaller than most of the companies we track.

Quality (9): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CRVO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CRVO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15$20$25Oct 25Jan 26Apr 26Jul 26CRVOHigh $25Median $15Low $9

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says6 analysts
6 Buy0 Hold0 Sell
Low $9Median $15High $25

The green dot is the last close — the median target sits +472.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
12 Aug 2026HC Wainwright & Co.ReiteratesBuy$25
10 Aug 2026Canaccord GenuityMaintainsBuy$27 → $18
15 July 2026HC Wainwright & Co.ReiteratesBuy$25
15 July 2026HC Wainwright & Co.ReiteratesBuy—
13 July 2026HC Wainwright & Co.ReiteratesBuy$25
13 July 2026HC Wainwright & Co.ReiteratesBuy—
9 July 2026HC Wainwright & Co.ReiteratesBuy$25
9 July 2026HC Wainwright & Co.ReiteratesBuy—
23 Apr 2026HC Wainwright & Co.ReiteratesBuy—
22 Apr 2026D. Boral CapitalMaintainsBuy—
8 Apr 2026D. Boral CapitalMaintainsBuy—
19 Mar 2026D. Boral CapitalMaintainsBuy—
18 Mar 2026Chardan CapitalMaintainsBuy—
18 Mar 2026Roth CapitalMaintainsBuy—
16 Mar 2026D. Boral CapitalMaintainsBuy—
5 Mar 2026Chardan CapitalMaintainsBuy—
4 Mar 2026D. Boral CapitalMaintainsBuy—
18 Feb 2026D. Boral CapitalMaintainsBuy—
18 Dec 2025Cantor FitzgeraldInitiatesOverweight—
18 Dec 2025HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CRVO appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

CRVO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

CervoMed, Inc. (CRVO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
4.9×

Cheaper than 66% of US stocks

Price / sales
119.6×

Cheaper than 4% of US stocks

Price / book
1.5×

Cheaper than 56% of US stocks

EV / EBITDA
−0.5×

Cheaper than 64% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
−9407.0%

Higher than 2% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−107.6%

Higher than 12% of US stocks

Return on assets
−60.8%

Higher than 6% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

CRVO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CRVOCervoMed, Inc.$39.6M
29
ALGSAligos Therapeutics, Inc.$41.3M
75
HOWLWerewolf Therapeutics, Inc.$42.4M
80
EDSAEdesa Biotech, Inc.$42.7M
58
TVGNTevogen, Inc.$43.3M
15
MCRBSeres Therapeutics, Inc.$43.7M
50
KPTIKaryopharm Therapeutics, Inc.$44.2M
65

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own CervoMed, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CRVO news & analysis

CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

GlobeNewsWire · 10 Aug 2026positive

CervoMed reported its Q2 2026 financial results and corporate updates, highlighting progress toward a strategic partnership for a Phase 3 trial of neflamapimod in DLB, new supportive clinical data, and two equity financings raising approximately $20.5 million to extend its cash runway through Q3 2027.

Why it matters — A CRVO watcher would care because the company is advancing its lead asset neflamapimod toward a pivotal Phase 3 trial for DLB, has secured regulatory designation in the UK, and raised funds to support operations through late 2027.

CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference

GlobeNewsWire · 5 Aug 2026neutral

CervoMed announced that its management will participate in a fireside chat and one-on-one investor meetings at the Canaccord Genuity 46th Annual Growth Conference, held in Boston on August 11, 2026. During the fireside chat, management will share recent progress in neflamapimod's clinical development program.

Why it matters — A CervoMed watcher would care because the conference gives management a venue to publicly discuss recent developments in the company's lead clinical program, neflamapimod.

CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB)

GlobeNewsWire · 4 Aug 2026positive

CervoMed announced that neflamapimod has been awarded an Innovation Passport designation under the UK Innovative Licensing and Access Pathway (ILAP) for the treatment of dementia with Lewy bodies (DLB). The designation is designed to support accelerated time to market and help expedite patient access to potentially transformative investigational medicines.

Why it matters — A CRVO watcher would care because the ILAP Innovation Passport could help accelerate regulatory review and market access for neflamapimod in the UK, a potential milestone for the company's lead dementia candidate.

FAQ

Frequently asked questions about CRVO stock

What is the CRVO stock price forecast for 2026-2027?

The 6 Wall Street analysts covering CervoMed, Inc. have a median 12-month price target of $15, with estimates ranging from $9 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CRVO stock a buy right now?

Of the 6 analysts covering CervoMed, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks CervoMed, Inc. 29 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CRVO?

As at 22 Aug 2026, CervoMed, Inc. ranks 29 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (84 of 100).

Will CRVO stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +472.5% from the last close, and Ticker Nerd's factor model ranks CervoMed, Inc. 29 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CRVO stock forecast for 2030?

No analyst covering CervoMed, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CRVO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $25 over the next 12 months.

How has CRVO stock performed over the past year?

CervoMed, Inc. returned -71.6% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does CervoMed, Inc. do?

CervoMed Inc. is a clinical-stage biotechnology company focused on developing treatments for age-related neurologic and brain disorders.

What is the latest news on CRVO?

The most recent item we track (GlobeNewsWire, 10 Aug 2026): "CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates". CervoMed reported its Q2 2026 financial results and corporate updates, highlighting progress toward a strategic partnership for a Phase 3 trial of neflamapimod in DLB, new supportive clinical data, and two equity financings raising approximately $20.5 million to extend its cash runway through Q3 2027.

Company

About CervoMed, Inc.

CervoMed Inc. is a clinical-stage biotechnology company focused on developing treatments for age-related neurologic and brain disorders. Headquartered in Boston, Massachusetts, CervoMed concentrates its efforts on central nervous system (CNS) diseases characterized by neurodegeneration, such as dementia with Lewy bodies and early Alzheimer’s disease. The company’s primary product candidate, neflamapimod, is an orally administered, small-molecule drug designed to cross the blood–brain barrier and inhibit the p38 alpha MAP kinase enzyme, a key driver of synaptic dysfunction in neurodegenerative conditions. By targeting this mechanism, CervoMed aims to address the reversible aspects of neuronal impairment associated with these disorders. Neflamapimod is being evaluated in mid-stage clinical trials, including a Phase 2b study in dementia with Lewy bodies, and is also supported by preclinical data in stroke recovery. Within the healthcare and biotechnology landscape, CervoMed plays a specialized role in advancing disease-modifying therapeutic candidates for complex CNS indications with significant unmet medical need.

CEO Dr. John J. Alam M.D. · 15 employees · United States · https://www.cervomed.com